

WHO Product Development for Vaccines Advisory Committee Meeting (PD-VAC)

7-9 September 2015

Venue: Salle D, WHO HQ, Geneva, Switzerland

Chair: David Kaslow

AGENDA

Day 1, Monday, 7 September 2015

Time	Presenter
09:00 - 09:15	Welcome and Introductions
	Jean-Marie Okwo-Bele
	<i>Director, Immunization, Vaccines & Biologicals, WHO</i>
09:15 – 09:35	The scope of PD-VAC, the objectives of this meeting and the 2014-2015 year for vaccine development
	Vasee Moorthy – <i>IVR, WHO</i>
09:35 – 09:50	Timelines for R&D reporting for Global Vaccine Action Plan & maternal immunization activities in influenza of relevance to product development – Joachim Hombach – <i>IVR, WHO</i>
09:50 – 10:05	Methods and interim results from Guinea ring vaccination Ebola Vaccine trial
	Ana Maria Henao Restrepo – <i>IVR, WHO</i>
10:05 – 10:20	Update on product development aspects of Meningococcal A Vaccine Project
	Marie-Pierre Preziosi – <i>IVR, WHO</i>
10:20 – 10:40	Update from SAGE committee, in relation to PD-VAC activities
	Jon Abramson, <i>Chair, SAGE</i>
10:40 – 11:00	Discussion
11:00 - 11:30	Coffee
11:30 – 12:30	Emergency R&D Preparedness
	A WHO Blueprint for Emergency R&D Preparedness (15 mins) Vasee Moorthy <i>on behalf of Blueprint team</i>
	MERS case study (15 mins) Kayvon Modjarrad – <i>Consultant, WHO</i>
12:30 – 13:30	LUNCH
13:30 – 14:00	Target Product Profiles for vaccines against emergency pathogens. Ebola as first case study
	David Kaslow / Vasee Moorthy
14:00 – 15:15	Respiratory Syncytial Virus (RSV)
	Ruth Karron - <i>Professor, Johns Hopkins University School of Public Health</i> Outcome of 2015 WHO RSV vaccine consultation (20 minutes)
	Update on RSV Roadmap (10 mins) Birgitte Giersing – <i>IVR, WHO</i>

	Update on Preferred Product Characteristics for RSV vaccines (10 mins)
	Kayvon Modjarrad - <i>Consultant, WHO</i>
15:15 – 15:30	Coffee
15:30 – 16:30	Group B Streptococcus
	Immaculada Margarit Y Ros – <i>GSK Vaccines</i>
	Vaccine development pipeline: progress and challenges (30 minutes)
	Discussion (30 minutes)
16:30 – 17:30	Group A Streptococcus
	Andrew Steer - <i>Professor, University of Melbourne</i>
	Update on vaccine development progress and future directions (30 minutes)
	Discussion (30 minutes)
Day 2, Tuesday, 8 September 2015	
09:00 – 11:00	Enteric Pathogens (ETEC, Shigella, Norovirus)
	Duncan Steele <i>Deputy Director and Strategic Lead: Enteric Vaccines, Bill and Melinda Gates Foundation</i>
	Vaccine development progress for ETEC vaccines (20 minutes)
	Discussion (25 minutes)
	Vaccine development progress for Shigella vaccines (25 minutes)
	Discussion (25 minutes)
	Vaccine development progress for Norovirus vaccines (10 minutes)
	Discussion (15 minutes)
11:00 - 11:15	Coffee break
11.15 – 12.30	Tuberculosis
	Mark Hatherill <i>Director, South African Tuberculosis Vaccine Initiative</i>
	Update on vaccine development progress and future directions (30 minutes)
	Discussion (45 minutes)
12:30 – 13:30	LUNCH
13:30 – 14.45	HIV
	Glenda Gray <i>President and CEO of the South African Medical Research Council</i>
	Update on vaccine development progress and future directions (30 minutes)
	Discussion (45 minutes)
14.45 – 15.45	HSV
	Carolyn Deal <i>Chief, Sexually Transmitted Diseases Branch, NIAID, NIH</i>
	Update on vaccine development progress and future directions (30 minutes)
	Discussion, (30 minutes)
15:45 – 16:00	Coffee break
16:00 – 17.15	Malaria

	Patrick Duffy. <i>Chief, Laboratory of Malaria Immunology and Vaccinology, NIAID</i>
	Update on vaccine development progress and future directions (30 minutes)
	Discussion (45 minutes)
17:15 – 17:30	GAVI criteria and the process for the vaccine investment strategy
	Judith Kallenberg - <i>Head of Policy, GAVI Alliance</i>

Day 3, Wednesday, 9 September 2015

09:00 – 10:15	Dengue
	Anna Durbin <i>Associate Professor, Johns Hopkins Bloomberg School of Public Health</i>
	Vaccine development pipeline: progress and challenges (30 minutes)
	Joachim Hombach: WHO role, current and future activities (5 minutes)
	Discussion (40 minutes)
10:15 – 11:00	Chikungunya
	David Beasley, <i>Associate Professor, Dept. of Microbiology & Immunology, University of Texas Medical Branch</i>
	Outcomes from NIH/WHO Chikungunya meeting and vaccine development progress (20 mins)
	Discussion (25 mins)
11:00 – 11:15	Coffee
11:15 – 12:30	Universal Influenza Vaccines
	Barney Graham <i>Deputy Director, Vaccine Research Center, NIAID/NIH</i>
	Update on vaccine development progress and future directions (30 minutes)
	Discussion (45 minutes)
12:30 – 13:30	LUNCH
13:30 – 14:00	Wrap up open session
	David Kaslow – <i>PDVAC Chair, WHO</i>
14:00 – 17:00	Committee closed session (with coffee break)